Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAUTAM JAYRAM

Allopathic & Osteopathic Physicians Urology

NPI
1265669683
CMS profile
428410
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$242,497.72

287 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 6 of 6; records 251–287 of 287 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAUTAM JAYRAM

NPI 1265669683 · CMS profile ID 428410

Allopathic & Osteopathic Physicians / Urology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–287 of 287 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265669683?year=2025&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAUTAM JAYRAM, NPI 1265669683, CMS profile ID 428410. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–287 of 287 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265669683?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GAUTAM JAYRAM, NPI 1265669683, CMS profile ID 428410. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–287 of 287 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265669683?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GAUTAM JAYRAM, NPI 1265669683, CMS profile ID 428410, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–287 of 287 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1265669683?year=2025&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

287 matching records · $242,497.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 287 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–287 of 287.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dendreon Pharmaceuticals LLC $1.7602/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245002963 CMS
PFIZER INC. $24.7302/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228887854 CMS
PROGENICS PHARMACEUTICALS, INC. $25.8602/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245221277 CMS
Ferring Pharmaceuticals Inc. $1,470.0002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242070340 CMS
Janssen Biotech, Inc. $4,162.5002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174892551 CMS
Telix Pharmaceuticals $2,840.0002/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1189634781 CMS
Telix Pharmaceuticals $3,550.0002/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1189634783 CMS
Janssen Biotech, Inc. $131.4702/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174895967 CMS
Janssen Biotech, Inc. $39.8602/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174903302 CMS
AstraZeneca Pharmaceuticals LP $21.8802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206556489 CMS
Janssen Biotech, Inc. $142.8502/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174895729 CMS
Janssen Biotech, Inc. $29.4202/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174881618 CMS
AstraZeneca Pharmaceuticals LP $14.3702/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206718355 CMS
AstraZeneca Pharmaceuticals LP $73.2002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207057884 CMS
Ferring Pharmaceuticals Inc. $15.5502/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242070332 CMS
Ferring Pharmaceuticals Inc. $21.8202/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242070334 CMS
Ferring Pharmaceuticals Inc. $174.8802/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242070336 CMS
Ferring Pharmaceuticals Inc. $124.9902/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242070338 CMS
IMMUNITYBIO, INC. $26.6302/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233172440 CMS
Janssen Biotech, Inc. $139.7902/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174895717 CMS
Sumitomo Pharma America, Inc. $29.1102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176670657 CMS
PFIZER INC. $21.4701/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228864412 CMS
Bayer Healthcare Pharmaceuticals Inc. $5.3901/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225590570 CMS
PFIZER INC. $2,500.0001/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1230483885 CMS
AstraZeneca Pharmaceuticals LP $28.5001/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206574106 CMS
Ferring Pharmaceuticals Inc. $23.8801/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242070330 CMS
PFIZER INC. $2,000.0001/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1230485183 CMS
Dendreon Pharmaceuticals LLC $134.5401/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245002959 CMS
Dendreon Pharmaceuticals LLC $6.0401/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245002957 CMS
ABBVIE INC. $30.2401/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202118630 CMS
Dendreon Pharmaceuticals LLC $23.4201/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245002955 CMS
IMMUNITYBIO, INC. $5.9201/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233171720 CMS
Ferring Pharmaceuticals Inc. $1,470.0001/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242070324 CMS
Ferring Pharmaceuticals Inc. $1,470.0001/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242070326 CMS
Ferring Pharmaceuticals Inc. $1,470.0001/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242070328 CMS
Telix Pharmaceuticals $300.9501/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189634779 CMS
Sumitomo Pharma America, Inc. $25.2901/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176670655 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $100,423.78 148
PY2020 $77,833.74 71
PY2021 $100,788.17 115
PY2022 $144,116.50 163
PY2023 $210,648.31 210
PY2024 $153,029.84 232
PY2025 $242,497.72 287

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $643,293.19 43
PY2024 Principal investigator $1,564,338.82 48
PY2023 Principal investigator $2,869,998.64 31
PY2022 Principal investigator $4,051,173.46 19
PY2021 Principal investigator $3,879,689.27 11
PY2020 Principal investigator $1,532,856.31 200
PY2019 Principal investigator $495,375.92 107

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $7,764.03 12/31/2025 Non-covered Recipient Entity
Urology Associates Nashville, TN
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1232925937
Principal investigator 1 Merck Sharp & Dohme LLC $22,150.54 12/31/2025 Non-covered Recipient Entity
Urology Associates Nashville, TN
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927471
Principal investigator 1 Merck Sharp & Dohme LLC $12,322.38 12/31/2025 Non-covered Recipient Entity
Urology Associates Nashville, TN
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927711
Principal investigator 1 Merck Sharp & Dohme LLC $11,014.20 12/31/2025 Non-covered Recipient Entity
Urology Associates
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934712
Principal investigator 1 PFIZER INC. $13,200.00 12/27/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER No dispute reported 06/30/2026 1228807397
Principal investigator 1 Janssen Research & Development, LLC $5,740.00 12/22/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175396836
Principal investigator 1 Janssen Research & Development, LLC $519.00 12/18/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175396801
Principal investigator 1 Janssen Research & Development, LLC $2,699.00 12/15/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396793
Principal investigator 1 PFIZER INC. $179.66 11/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER No dispute reported 06/30/2026 1228807392
Principal investigator 1 Janssen Research & Development, LLC $15,512.00 11/24/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396892
Principal investigator 1 Janssen Research & Development, LLC $5,996.00 11/07/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175396909
Principal investigator 1 Janssen Research & Development, LLC $3,845.00 10/27/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396920
Principal investigator 1 Ferring Pharmaceuticals AS $4,290.00 10/14/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242061172
Principal investigator 1 Janssen Research & Development, LLC $10,732.00 10/09/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175397013
Principal investigator 1 Janssen Research & Development, LLC $2,188.00 10/03/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175396748
Principal investigator 1 Merck Sharp & Dohme LLC $66,420.48 08/31/2025 Non-covered Recipient Entity
Urology Associates
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934714
Principal investigator 1 Janssen Research & Development, LLC $5,382.00 08/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396805
Principal investigator 1 Janssen Research & Development, LLC $3,808.00 08/11/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175396856
Principal investigator 1 Janssen Research & Development, LLC $3,934.00 07/28/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396992
Principal investigator 1 Janssen Research & Development, LLC $1,509.00 07/14/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175273401
Principal investigator 1 Janssen Research & Development, LLC $1,720.00 06/30/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396761
Principal investigator 1 Janssen Research & Development, LLC $1,347.00 06/30/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175396957
Principal investigator 1 Janssen Research & Development, LLC $7,693.00 06/27/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396850
Principal investigator 1 Janssen Research & Development, LLC $35,342.00 06/19/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396916
Principal investigator 1 Janssen Research & Development, LLC $823.00 06/19/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396926
Principal investigator 1 Janssen Research & Development, LLC $2,188.00 06/02/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175396699
Principal investigator 1 Janssen Research & Development, LLC $11,368.00 05/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396999
Principal investigator 1 Janssen Research & Development, LLC $4,274.00 05/19/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175396861
Principal investigator 1 Ferring Pharmaceuticals AS $2,281.50 05/15/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242060329
Principal investigator 1 Janssen Research & Development, LLC $7,023.00 05/12/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175396773
Principal investigator 1 Janssen Research & Development, LLC $1,623.00 05/01/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396778
Principal investigator 1 Janssen Research & Development, LLC $1,509.00 04/28/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175274372
Principal investigator 1 Janssen Research & Development, LLC $3,279.00 04/07/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175396784
Principal investigator 1 Janssen Research & Development, LLC $17,364.00 03/31/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175396986
Principal investigator 1 Janssen Research & Development, LLC $3,854.00 03/28/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175396888
Principal investigator 1 Janssen Research & Development, LLC $2,716.00 03/28/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175397008
Principal investigator 1 Janssen Research & Development, LLC $10,665.00 03/10/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175396743
Principal investigator 1 Janssen Research & Development, LLC $5,677.00 03/03/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396974
Principal investigator 1 Janssen Research & Development, LLC $1,509.00 02/13/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175273795
Principal investigator 1 Janssen Research & Development, LLC $7,479.00 02/10/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175396843
Principal investigator 1 AstraZeneca Pharmaceuticals LP $252,934.60 01/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES, PC
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185541458
Principal investigator 1 Merck Sharp & Dohme LLC $48,731.80 01/29/2025 Non-covered Recipient Entity
Urology Associates
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934710
Principal investigator 1 Janssen Research & Development, LLC $12,687.00 01/27/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175396951

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $60,383.21 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $59,200.75 1
PY2022 Amount invested $8,516.72 1
PY2022 Value of interest $28,579.67 1
PY2021 Amount invested $6,457.65 1
PY2021 Value of interest $25,087.53 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $47,768.94 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $20,456.55 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $153.92 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771491
PY2024 SN Holdings, LLC $0.00 $60,229.29 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773239
PY2023 SN Holdings, LLC $0.00 $59,200.75 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887265
PY2022 SN Holdings, LLC $8,516.72 $28,579.67 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609259
PY2021 SN Holdings, LLC $6,457.65 $25,087.53 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125009
PY2020 UroGPO LLC $0.00 $47,768.94 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139597
PY2019 UroGPO LLC $0.00 $20,456.55 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690775177